Category Specific RSS

pxs

Fibrosis is the simple disease process that’s more important than you think

How does a company with a lead asset cancer drug also get into dermatology?  What does blood cancer and keloid…

3 years ago

“Scars are more than skin deep”: Why Professor Fiona Wood is working with this biotech to melt away scars

The skin is one of the most overlooked, complex and essential organs. It is the body’s first line of defence…

3 years ago

International expansion as more hospitals register for Pharmaxis’ cancer treatment trials

Clinical stage pharmaceutical company Pharmaxis (PXS: ASX) is full steam ahead with their Phase 2 clinical trial for flagship drug,…

4 years ago

Out-the-box thinkers are just what the myelofibrosis treatment market needs

The pharmaceutical industry is an incredibly competitive space with new drug discoveries cropping up all the time, giving hope that…

4 years ago

Making their mark: Pharmaxis to continue clinical trials in revolutionary anti-skin scarring drug

In the wake of their oversubscribed capital raising effort, clinical stage pharmaceutical company Pharmaxis (ASX: PXS) is forging ahead with…

4 years ago

Momentum continues for Pharmaxis with $1.4m in grants following oversubscribed raise

Just days after closing their oversubscribed $9.8 million capital raise, drug developer Pharmaxis (ASX: PXS) has seen further funding devoted…

4 years ago